Deireadh Fómhair 2021: Tá Cabozantinib (Cabometyx, Exelixis, Inc.) ceadaithe ag an Riarachán Bia agus Drugaí d’othair aosacha agus péidiatraiceacha 12 bliana d’aois agus níos sine a bhfuil thyroi difreáilte chun cinn áitiúil nó metastatach déanta acu go háitiúil.
Lenvatinib (Lenvima) New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was app..